Treatment Strategies and Survival Outcomes of Patients with EGFR-mutated NSCLC and leptomeningeal metastasis

被引：0
|
作者：
Fan, Y. [1 ]
Wu, H. [1 ]
Chen, K. [1 ]
机构：
[1] Zhejiang Canc Hosp, Hangzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Leptomeningeal metastases; EGFR TKI resistance; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-30
引用
收藏
页码：S652 / S652
页数：1
相关论文
共 50 条
  • [31] Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report
    Merkhofer, Cristina M.
    Baik, Christina S.
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (06):
  • [32] Depth of Response to First-Line EGFR TKI Does Not Predict Survival in EGFR-Mutated NSCLC Patients
    Wu, Ting-Hui
    Hsiue, Emily
    Lee, Jih-Hsiang
    Yang, James Chih-Hsin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S386 - S387
  • [33] Proteogenomic Analysis of CSF Reveals Distinct Molecular Patterns of Leptomeningeal Metastases in EGFR-Mutated NSCLC
    Zheng, M-M
    Lin, S-H
    Li, Y-S
    Yin, K.
    Li, P.
    Zhang, X-C
    Gao, S-X
    Zhou, Q.
    Tu, H-Y
    Yang, J-J
    Chen, H-J
    Pan, Y.
    Wang, B-C
    Wang, Z.
    Xu, C-R
    Xiao, F-M
    Zhong, W-Z
    Yan, H-H
    Tang, L-B
    Wu, L.
    Zeng, L.
    Liu, S-Y. M.
    Wong, C. C.
    Wu, Y-L
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S80 - S81
  • [34] Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicity
    Jokic, Vera
    Savic-Vujovic, Katarina
    Spasic, Jelena
    Stanic, Nemanja
    Marinkovic, Mladen
    Radosavljevic, Davorin
    Cavic, Milena
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (06) : 673 - 679
  • [35] Gefitinib and Pemetrexed Improve Survival in EGFR-Mutated NSCLC - Tarring all Patients With the Same Brush?
    Arulananda, Surein
    John, Thomas
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (01) : 12 - 14
  • [36] Upfront radiation versus EGFR-TKI: which is the best approach for EGFR-mutated NSCLC patients with brain metastasis?
    Passiglia, Francesco
    Rolfo, Christian
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S533 - S536
  • [37] Resistance landscape to almonertinib in EGFR-mutated NSCLC
    Tian, M.
    Lu, Z.
    Chen, S.
    Lu, G.
    Bu, F.
    Deng, W.
    Ding, R.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1017 - S1017
  • [38] Outcomes of surgery and subsequent therapy for central nervous system oligoprogression in EGFR-mutated NSCLC patients
    Perng, Pang-Shuo
    Hsu, Heng-Juei
    Lee, Jung-Shun
    Wang, Liang-Chao
    Huang, Chih-Yuan
    Tien, Chih-Hao
    Lai, Yu-Hsuan
    Su, Po-Lan
    Hsu, Hao-Hsiang
    Chen, Liang-Yi
    Lee, Po-Hsuan
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [39] Outcomes of surgery and subsequent therapy for central nervous system oligoprogression in EGFR-mutated NSCLC patients
    Pang-Shuo Perng
    Heng-Juei Hsu
    Jung-Shun Lee
    Liang-Chao Wang
    Chih-Yuan Huang
    Chih-Hao Tien
    Yu-Hsuan Lai
    Po-Lan Su
    Hao-Hsiang Hsu
    Liang-Yi Chen
    Po-Hsuan Lee
    World Journal of Surgical Oncology, 21
  • [40] High-Dose Furmonertinib in Patients With EGFR-Mutated NSCLC and Leptomeningeal Metastases: A Prospective Real-World Study
    Chen, Haiyang
    Yang, Sen
    Wang, Lili
    Wu, Yingxi
    Wu, Yufeng
    Ma, Shuxiang
    He, Zhen
    Zhang, Cuicui
    Liu, Yang
    Tang, Haoran
    Dong, Hang
    Wang, Qiming
    JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (01) : 65 - 75
12345